|
| 38065715 | Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study. | J Clin Lipidol | 2024 |
| 37937463 | Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease. | Circulation | 2024 |
| 37632469 | Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. | Circulation | 2024 |
| 37419784 | Clinical trials to improve outcomes in patients with elevated Lp(a) undergoing PCI: The time has arrived. | J Clin Lipidol | 2023 |
| 37607461 | Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis. | Atherosclerosis | 2023 |
| 38039351 | Exploring apolipoprotein C-III: Pathophysiological and pharmacological relevance. | | 2023 |
| 37848630 | Oxidized phospholipids in cardiovascular disease. | | 2023 |
| 37938756 | Lipoprotein(a), platelet function and cardiovascular disease. | | 2023 |
| 38065307 | Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. | | 2023 |
| 37338713 | On-treatment platelet reactivity through the thromboxane A or P2Y12 platelet receptor pathways is not affected by pelacarsen. | | 2023 |
| 37211249 | High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction. | | 2023 |
| 36511156 | Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA. | Hypertension | 2023 |
| 37077580 | Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression. | | 2023 |
| 37264561 | Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics. | | 2023 |
| 37137588 | Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. | | 2023 |
| 37263914 | Effects of mixed nut consumption on LDL cholesterol, lipoprotein(a), and other cardiometabolic risk factors in overweight and obese adults. | | 2023 |
| 36807395 | Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. | Nat Rev Cardiol | 2023 |
| 36624274 | The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. | Nat Rev Cardiol | 2023 |
| 37357049 | Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis. | J Clin Lipidol | 2023 |
| 36990544 | Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). | | 2023 |
| 37164837 | APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. | | 2023 |
| 37100699 | Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. | | 2023 |
| 36529659 | Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. | | 2023 |
| 36454263 | Integrated Assessment of Phase 2 Data on GalNAc-Conjugated 2'--Methoxyethyl-Modified Antisense Oligonucleotides. | Nucleic Acid Therapeutics | 2023 |
| 37487514 | Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study. | Lancet Diabetes Endocrinol | 2023 |
| 34995986 | Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. | Atherosclerosis | 2022 |
| 36175048 | Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. | J Am Coll Cardiol | 2022 |
| 35902351 | Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. | J Clin Lipidol | 2022 |
| 35653195 | Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. | JCI insight | 2022 |
| 36007992 | Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. | Journal of the American College of Cardiology | 2022 |
| 35688187 | Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). | Journal of Lipid Research | 2022 |
| 35803063 | Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. | Atherosclerosis | 2022 |
| 36320028 | Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation. | Lipids in Health and Disease | 2022 |
| 36402670 | Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study. | Journal of Clinical Lipidology | 2022 |
| 36396202 | Lipoprotein(a) and LDL-C: The Relevance of Equivalence. | Journal of the American College of Cardiology | 2022 |
| 36252994 | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. | Open Heart | 2022 |
| 34213715 | Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. | Journal of Thrombosis and Thrombolysis | 2022 |
| 34508626 | Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. | European Heart Journal | 2022 |
| 35025993 | Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. | Eur Heart J | 2022 |
| 35210031 | Lipoprotein(a) and Coronary Calcium: Clinical Management and Potential Design of Primary Prevention Trials. | Journal of the American College of Cardiology | 2022 |
| 35144769 | Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. | Atherosclerosis | 2022 |
| 35057908 | Lipoprotein(a) and CT Angiography: Novel Insights Into High-Risk Plaque Progression. | Journal of the American College of Cardiology | 2022 |
| 34531030 | PCSK9 Inhibition and Oxidized Phospholipids. | J Am Coll Cardiol | 2021 |
| 33638113 | Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. | Neurology and Therapy | 2021 |
| 33798466 | Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. | Lancet Diabetes and Endocrinology,The | 2021 |
| 33636163 | Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. | J Lipid Res | 2021 |
| 34278710 | Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. | Aging Cell | 2021 |
| 34222719 | Antisense Inhibition of Angiotensinogen With IONIS-AGT-L: Results of Phase 1 and Phase 2 Studies. | JACC: Basic to Translational Science | 2021 |
| 33791697 | The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection. | bioRxiv | 2021 |
| 34000000 | Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. | European Heart Journal | 2021 |